Figure 6.

Yes‐associated protein (YAP) signaling is activated in sarcopenia coordinately with activation of Wnt signaling. (a) Western blotting of YAP in muscle from young and aged mice (left) and densitometry quantification (right) (n = 6). (b) Western blotting of YAP in muscles of 17‐, 64‐, and 80‐year‐old human volunteers. (c) Western blotting of active β‐catenin (ABC) and YAP using the nuclear fraction from (pro)renin receptor ((P)RR)‐expressing C2C12 myoblasts (left) and densitometry quantification (right) (n = 6). (d) Relative expression levels of ankrd1 and ctgf mRNA in (P)RR‐expressing myoblasts (n = 6). (e) Number of MHC‐positive myotubes or (f) nuclei per differentiated myotube from (P)RR‐expressing myoblasts or controls treated with verteporfin or vehicle (n = 6). (g) Western blotting of YAP in gastrocnemius muscle, soleus muscle, heart, liver, and kidney of (P)RR‐Tg mice (left) and densitometry quantification (right) (n = 5). (h) Western blotting of YAP in muscles of WT and (P)RR‐Tg mice treated with DKK1 or vehicle (left) and densitometry quantification (right) (n = 6). (i) Relative expression levels of ankrd1 and ctgf mRNA in muscles from WT and (P)RR‐Tg mice treated with DKK1 or vehicle (n = 7). (j) Western blotting of YAP in muscles of WT and (P)RR‐Tg mice treated with nAb or vehicle (left) and densitometry quantification (right) (n = 6). (k) Relative expression levels of ankrd1 and ctgf mRNA in muscles from WT and (P)RR‐Tg mice treated with verteporfin or vehicle (n = 6). (l) Comparison of the weight ratio of verteporfin‐treated to vehicle‐treated TA in WT and (P)RR‐Tg mice (n = 7). (m) Western blotting of ABC, YAP, and DKK1 in muscles of WT and (P)RR‐Tg mice on day 5 after verteporfin or vehicle addition (n = 6). Data represent the mean ± SEM. *p < 0.05 and **p < 0.01; n.s., not significant, as determined by the Mann–Whitney U test (b,c,d,g,l) or ANOVA followed by the Bonferroni post hoc correction (e,f,h,i,j,k)